医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2012年
11期
2063-2064
,共2页
疱疹,带状/治疗%面部皮肤病%神经传导阻滞%星状神经节
皰疹,帶狀/治療%麵部皮膚病%神經傳導阻滯%星狀神經節
포진,대상/치료%면부피부병%신경전도조체%성상신경절
herpes zoster /T H%facial dermatoses%nerve block%stellate ganglion
[目的]探讨星状神经节阻滞联合药物治疗头面部带状疱疹的临床疗效.[方法]55例头面部带状疱疹患者随机分为两组,治疗组( n =28,A 组)和对照组( n =27,B 组),治疗组采用星状神经节阻滞,联合曲马多、加巴喷丁等药物治疗,对照组采用经典药物治疗.采用 VAS 评分评估两组患者治疗前后疼痛程度变化.[结果]治疗前,治疗组 VAS 平均为7.68±0.32,对照组为7.53±0.27;治疗五周后,治疗组 VAS 平均为2.42±0.26,对照组3.60±0.34.治疗前、后,A 组和 B 组同组内各时间点的 VAS 分别随时间变化而减少,且两两比较差异均具有显著性( P <0.05).治疗后二周起 A 、B 组组间 VAS 比较,差异均具有显著性( P<0.05).[结论]星状神经节阻滞联合药物治疗头面部带状疱疹有效、安全,值得临床推广应用.
[目的]探討星狀神經節阻滯聯閤藥物治療頭麵部帶狀皰疹的臨床療效.[方法]55例頭麵部帶狀皰疹患者隨機分為兩組,治療組( n =28,A 組)和對照組( n =27,B 組),治療組採用星狀神經節阻滯,聯閤麯馬多、加巴噴丁等藥物治療,對照組採用經典藥物治療.採用 VAS 評分評估兩組患者治療前後疼痛程度變化.[結果]治療前,治療組 VAS 平均為7.68±0.32,對照組為7.53±0.27;治療五週後,治療組 VAS 平均為2.42±0.26,對照組3.60±0.34.治療前、後,A 組和 B 組同組內各時間點的 VAS 分彆隨時間變化而減少,且兩兩比較差異均具有顯著性( P <0.05).治療後二週起 A 、B 組組間 VAS 比較,差異均具有顯著性( P<0.05).[結論]星狀神經節阻滯聯閤藥物治療頭麵部帶狀皰疹有效、安全,值得臨床推廣應用.
[목적]탐토성상신경절조체연합약물치료두면부대상포진적림상료효.[방법]55례두면부대상포진환자수궤분위량조,치료조( n =28,A 조)화대조조( n =27,B 조),치료조채용성상신경절조체,연합곡마다、가파분정등약물치료,대조조채용경전약물치료.채용 VAS 평분평고량조환자치료전후동통정도변화.[결과]치료전,치료조 VAS 평균위7.68±0.32,대조조위7.53±0.27;치료오주후,치료조 VAS 평균위2.42±0.26,대조조3.60±0.34.치료전、후,A 조화 B 조동조내각시간점적 VAS 분별수시간변화이감소,차량량비교차이균구유현저성( P <0.05).치료후이주기 A 、B 조조간 VAS 비교,차이균구유현저성( P<0.05).[결론]성상신경절조체연합약물치료두면부대상포진유효、안전,치득림상추엄응용.
Objective] To evaluate the clinical efficacy of stellate ganglion block (SGB) combined with drugs for the treatment of patients with herpes zoster on head and face .[Methods] A total of 55 patients with herpes zoster on head and face were randomly divided into treatment group (n = 28 ,group A) and control group (n = 27 ,group B) .The treatment group received SGB combined with drug therapy such as tramadol and gaba‐pentin .The control group was given classic drug therapy .The change of pain before and after treatment were evaluated by using visual analogue scale(VAS) .[Results] Before the treatment ,the average VAS of the treat‐ment group and control group was 7 .68 ± 0 .32 and 7 .53 ± 0 .27 ,respectively .After 5 weeks of treatment ,the average VAS of treatment group and control group were 2 .42 ± 0 .26 and 3 .60 ± 0 .34 ,respectively .The VAS at different time points in group A and group B before and after treatment decreased with the time ,and there was significant difference between two groups ( P < 0 .05) .After 2 weeks of treatment ,there was significant difference in VAS between group A and group B ( P < 0 .05) .[Conclusion] SGB combined with drugs for the treatment of herpes zoster on head and face is effective and safe ,so it is worthy of clinical promotion .
